imatinib has been researched along with Endocarditis, Loeffler in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Q | 1 |
| Liu, F | 1 |
| Qi, S | 1 |
| Qi, Z | 1 |
| Yan, XE | 1 |
| Wang, B | 1 |
| Wang, A | 1 |
| Wang, W | 2 |
| Chen, C | 1 |
| Liu, X | 1 |
| Jiang, Z | 1 |
| Hu, Z | 1 |
| Wang, L | 1 |
| Ren, T | 1 |
| Zhang, S | 1 |
| Yun, CH | 1 |
| Liu, Q | 1 |
| Liu, J | 1 |
| Řezníčková, E | 1 |
| Gucký, T | 1 |
| Kováčová, V | 1 |
| Ajani, H | 1 |
| Jorda, R | 1 |
| Kryštof, V | 1 |
2 other studies available for imatinib and Endocarditis, Loeffler
| Article | Year |
|---|---|
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Topics: Acrylamides; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Dose-Respons | 2018 |
Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; | 2019 |